Galena Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 104   

Articles published

GALE 1.51 +0.02 (1.34%)
price chart
Galena Biopharma, Inc. Short Interest Update
The short interest in Galena Biopharma, Inc. (NASDAQ:GALE) has declined from 23,613,713 on October 30,2015 to 23,428,628 on November 13,2015.
Galena Biopharma Inc Hedge Fund Sentiment Improved in Q2 2015
Galena Biopharma Inc (NASDAQ:GALE) hedge funds sentiment decreased to 1.43 in Q2 2015. Its down -0.23, from 1.66 in 2015Q1.
Company Shares of Galena Biopharma, Inc. (NASDAQ:GALE) Drops by -2%  News Watch International
Is Galena Biopharma Inc (GALE) A Good Stock To Buy?  Insider Monkey (blog)
Company Update (NASDAQ:GALE): Galena Biopharma Inc Completes Divestiture of ...
Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the sale of its Abstral´┐Ż (fentanyl) ...
3 Things Galena Biopharma Inc. Wants You to Know  Motley Fool
Galena jettisons Abstral for $12M  Seeking Alpha
Why Shares of Galena Biopharma, Inc. Spiked Today
What: Shares of Galena Biopharma (NASDAQ:GALE) climbed by over 12% on exceptional volume today after the company announced the publication of two abstracts for the upcoming American Society of Clinical Oncology, or ASCO, meeting being held May ...
Galena Biopharma Inc (GALE)'s Bullish Stance Reiterated at Maxim Ahead ...  Smarter Analyst
Galena Biopharma to Present at the Sachs Immuno-Oncology BD&L and ...  GlobeNewswire (press release)
Maxim Weighs In on Two Biotech Stocks: Galena Biopharma Inc (GALE), AEterna ...
Maxim analysts are weighing in on the small-cap biopharmaceutical company Galena Biopharma Inc (NASDAQ:GALE), and Canadian biotech company AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), after the companies presented clinical data at the ...
Momentum Stock in Focus - Galena Biopharma, Inc. (NASDAQ:GALE)
According to Zacks, Galena Biopharma, Inc. (NASDAQ:GALE) has been given a high momentum style score. The score calculation is based on a number of factors indicating that the stock might be at a favorable level to enter a position based on the recent ...
Maxim Reiterates Buy on Galena Biopharma Inc Following GALE-301 Phase 2a ...
In a research report published today, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Galena Biopharma Inc (NASDAQ:GALE) with a $7 price target, after the company announced that data from the GALE-301 Phase 2a portion of the Phase ...
Galena Biopharma Presents Positive GALE-301 Phase 2a Clinical Trial Data at ...  GlobeNewswire (press release)
Galena Biopharma, Inc. Analyst Rating Update
Research firm Zacks has rated Galena Biopharma, Inc. (NASDAQ:GALE) and has ranked it at 3, indicating that for the short term the shares are a hold.
Recent Analysts' Ratings Updates for Galena Biopharma (GALE)  Dakota Financial News
Galena Biopharma Given Outperform Rating at FBR & Co. (GALE)  Voice Chronicle
Stock Update (NASDAQ:GALE): Galena Biopharma Inc Reports 2Q15 Financial Results
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today reported its financial results ...
Galena Biopharma Comes Up Short in Q2 and Investors Pounce  Motley Fool
Analyst Price Target Update on Galena Biopharma, Inc.
Galena Biopharma, Inc. (NASDAQ:GALE): The mean short term price target for Galena Biopharma, Inc. (NASDAQ:GALE) has been established at $4.64 per share.
Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th ...  Nasdaq